Suppressing c-FOS expression by G-quadruplex ligands inhibits osimertinib-resistant non-small cell lung cancer
AbstractBackground. Osimertinib is the first-line therapy for patients with non-small cell lung cancer harboring epidermal growth factor receptor–activatin